HCPCS Code Descriptor:
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Route of Administration:
KYMRIAH is an Oncology drug manufactured by Novartis and administered via the Intravenous route of administration. The Q Code: Q2042 is aligned to the drug KYMRIAH.